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     Clenbuterol is a long-acting β2-adrenoceptor agonist and bronchodilator that is 
used for treatment of asthma, but the desired activities reside almost exclusively in the 
(-)-R-enantiomer.  Here, we examined enantioselectivity in the disposition of clenbuterol 
following administration of clenbuterol racemate to rats.   
     Concentrations of clenbuterol enantiomers in plasma, urine, and bile were 
determined by LC-MS/MS assay with a Chirobiotic T column.  This method was 
confirmed to show high sensitivity, specificity, and precision, and clenbuterol enantiomers 
in 0.1-mL volumes of plasma were precisely quantified at concentrations as low as 0.25 
ng/mL. The pharmacokinetic profiles of clenbuterol enantiomers following intravenous 
and intraduodenal administration of clenbuterol racemate (2 mg/kg) in rats were 
significantly different.  The distribution volume of (-)-R-clenbuterol (9.17 L/kg) was 
significantly higher than that of (+)-S-clenbuterol (4.14 L/kg).  Total body clearance of 
(-)-R-clenbuterol (13.5 mL/min/kg) was significantly higher than that of the 
(+)-S-enantiomer (11.5 mL/min/kg).  An in-situ absorption study in jejunal loops showed 
no difference in residual amount between the (-)-R- and (+)-S-enantiomers.  Urinary 
clearance was the same for the two enantiomers, but biliary excretion of (-)-R-clenbuterol 
was higher than that of the (+)-S-enantiomer.  The fractions of free (non-protein-bound) 
(-)-R- and (+)-S-clenbuterol in rat plasma were 48.8, and 33.1%, respectively.  These 
results indicated that there are differences in distribution and excretion of the clenbuterol 
enantiomers, and these may be predominantly due to enantioselective protein binding. 
  




     Many drugs are still formulated as racemic mixtures, though enantiomers may differ 
in their pharmacokinetic and pharmacodynamic properties. For example, S-(-)-ofloxacin, 
a new quinolone antibacterial agent, is 8-128 times more active than R-(+)-ofloxacin 
against both gram-positive and gram-negative bacteria [1,2].  In addition, conversion of 
S-(-)-ofloxacin to the glucuronide in rat liver microsomes is 7-fold greater than that of 
R-(+)-ofloxacin [3].  Recently, the histamine H1 antagonist levocetirizine and the sleep 
inducer eszopiclone have been approved by the FDA for use as optically active 
preparations [4].  On the other hand, only the S-enantiomer of thalidomide is teratogenic, 
but chiral inversion occurs readily in aqueous media and human serum, so that this 
finding does not imply the R-enantiomer is clinically safe [5,6].  Thus, information about 
enantiomeric conversion is important for drug product formulation. 
     Clenbuterol (4-amino-α-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol) is a 
long-acting β2-adrenoceptor agonist that is used as a bronchodilator for treatment of 
asthma [7].  It also possesses physiological properties, promoting the growth of muscle 
tissue and reduction of body fat [8-10].  Clenbuterol is commercially available as a 
racemic mixture of (-)-R- and (+)-S-enantiomers.  Beta2-stimulant activities such as 
bronchodilation and uterine relaxing activity are almost exclusively possessed by 
(-)-R-clenbuterol [11-14].  On the other hand, (+)-S-clenbuterol has been reported to 
cause adverse effects such as reduction of blood pressure, increase of blood glucose 
levels, and elevation of glucocorticoid levels [15].   
     The pharmacokinetics, tissue distribution and metabolism of clenbuterol have been 
studied in a number of species, including human [16-19].  Residual clenbuterol in meat 
and muscle tissue is also a matter of concern in the food industry and in connection with 
drug abuse [20-24].  However, there is no available information on stereoselectivity in 
the absorption, distribution, and excretion of clenbuterol.  Therefore, we investigated the 
4 
enantioselective disposition of clenbuterol in rats.  We also examined the 
interconvertibility of clenbuterol enantiomers in vitro and in vivo.   
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Materials and Methods 
Chemicals and Reagents  
     (rac)-Clenbuterol hydrochloride, ammonium formate, LC-MS grade water and 
LC-MS grade methanol were obtained from Sigma-Aldrich, Co. (St. Louis, MO, USA).  
Carvedilol used as an internal standard (IS) and acetonitrile were purchased from Wako 
Pure Chemical Industries, Ltd. (Osaka, Japan).  (-)-R- and (+)-S-clenbuterol 
enantiomers were obtained from Fujiyakuhin Co., Ltd (Saitama, Japan).  The purities of 
these compounds were 100%, and 93.6%, respectively.  The (-)-R-clenbuterol was free 
from (+)-S-clenbuterol, while the (+)-S-clenbuterol consisted of 93.0% (+)-S-clenbuterol 
and 7.0% (-)-R-clenbuterol.  All other solvents and reagents used were of reagent 
grade. 
 
Sample preparation for LC-MS/MS analysis 
     Plasma.  A 10-µL volume of methanol containing carvedilol (100 ng/mL) as an IS 
and 900 µL of acetonitrile were added to 100 µL of plasma in a 1.5-mL microcentrifuge 
tube.  This solution was mixed for 1 min on a vortex mixer, followed by centrifugation at 
18,000 g for 5 min.  The supernatant (900 µL) was applied to a solid-phase extraction 
column, SUPELCO HybridSPE®-Phospholipid (Supelco, PA, USA), and allowed to stand 
for 20 min.  The eluate was transferred into an autosampler vial, and 10 µL was injected 
into the LC-MS/MS system. 
 
     Urine and Bile.  A 10-µL volume of methanol containing carvedilol (100 ng/mL) as 
an IS and 900 µL of acetonitrile were added to 100 µL of urine or bile diluted 20-fold in 
distilled water.  This solution was mixed for 1 min on a vortex-mixer, followed by 
centrifugation at 18,000 g for 5 min.  The supernatant (900 µL) was applied to a 
solid-phase extraction column, SUPELCO HybridSPE®-Phospholipid (Supelco, PA, 
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USA), and allowed to stand for 20 min.  The eluate was transferred into an autosampler 
vial, and 10 µL was injected into the LC-MS/MS system.  
 
Chromatographic conditions 
     The HPLC system (Shimadzu Co., Kyoto, Japan) consisted of the following 
components: DGC-20A5 degasser, LC-20AD solvent delivery pump, SIL-20AC automatic 
sample injector, and CTO-20AC column oven.  The analytical column for 
enantioseparation was a 5-µm Chirobiotic T column, 100 x 2.1-mm i.d. (ASTEC, 
Whippany, NJ).  This column has a macrocyclic antibiotic chiral stationary phase.  The 
mobile phase was a mixture of methanol and water (95:5, v/v) containing 2.5 mM 
ammonium formate, and the flow rate was set at 0.2 mL/min.  The column was 
maintained at 40°C.  
 
Mass spectrometry conditions 
     Mass spectrometric (MS) analysis was conducted using an API 4000 triple 
quadrupole instrument (AB Sciex Inc., MA, USA), equipped with an electrospray 
ionization source (ESI) operating in the positive ion mode.  Analysis was performed in 
multiple reaction monitoring (MRM) mode by monitoring the ion transition from m/z 277.0 
[M+H]+→ 203.0 for clenbuterol enantiomers and m/z 407.1 → 100.0 for the IS.  The 
analytical parameters were as follows: ion spray, 5,500 V; declustering potential, 56 V; 
entrance potential, 10 V; collision energy, 23 V; collision cell exit potential, 12 V; 
temperature 600°C. Nitrogen was used as the collision gas.  The total run time was 20 
min.  The data were acquired and processed with Analyst 1.4™ software (AB Sciex, 
USA).  No endogenous peak interfering with determination of these compounds was 
observed in the chromatogram of blank plasma.  The retention times of (-)-R-clenbuterol, 
(+)-S-clenbuterol, and the IS were 12.8, 14.5, and 13.1 min, respectively.  The two 
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enantiomers were well separated. 
 
Calibration curves 
     The linear concentration range was determined by adding 10 µL of working 
standard solutions containing racemic clenbuterol to 100 µL of rat blank plasma.  The 
plasma samples were then assayed using the method described above.  The peak area 
ratios were calculated by dividing the peak area of the (-)-R- or (+)-S-clenbuterol signals 
by that of the IS and were plotted against the concentration of each compound. 
     The calibration graphs for the plasma assay were linear in the range of 0.25–50 
ng/mL for clenbuterol enantiomers when 1 ng of the IS was used (regression equations; y 
= 0.2637x + 0.0207, r2 = 0.9998 for (-)-R-clenbuterol, and y = 0.2662x + 0.0275, r2 = 
0.9999 for (+)-S-clenbuterol.)  Similarly, the calibration graphs were linear in the range 
of 50–250 ng/mL for clenbuterol enantiomers when 1 ng of the IS was used (regression 
equations; y = 0.23391x + 0.00612, r2 = 0.9998 for (-)-R-clenbuterol, and y = 0.23604x + 
0.0172, r2 = 0.9998 for (+)-S-clenbuterol).  The lower quantitation limit was 0.25 ng/mL. 
 
Accuracy and precision 
     To examine the accuracy and precision of the present method, three different 
racemic clenbuterol concentrations (2, 10, and 50 ng/mL; 1.0, 5.0, and 25 ng/mL of each 
enantiomer, respectively) were prepared in rat blank plasma.  For the evaluation of 
inter-assay precision, 0.1-mL aliquots of plasma were analyzed.  For intra-assay 
precision measurements, aliquots of the plasma samples were analyzed in duplicate on 
six consecutive days. 
     Reproducibility of the clenbuterol enantiomer analysis in rat plasma is summarized 
in Table 1.  For intra-assay precision, the mean coefficients of variation for 
(-)-R-clenbuterol and (+)-S-clenbuterol were 2.7 and 3.0%, respectively.  For inter-assay 
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precision, the mean coefficients of variation for (-)-R-clenbuterol and (+)-S-clenbuterol 
were 2.4% and 2.5%, respectively. 
 
Animals  
     Four male Wistar rats (200 - 250 g) were provided by Kumagai-shigeyasu Co., Ltd 
(Japan, Miyagi), and housed in cages with unlimited food and water, except that food was 
not provided for 12 hours before the experiment.  The animals were maintained on a 
12-hours light/dark cycle (light on from 7:00 to 19:00) at ambient temperature (22-24°C) 
and at 60% relative humidity.  All rats were deprived of food but given free access to 
water for 12 hours before the experiment.  
     The animal study was approved by the Ethics Committee for the Use of Animals of 
the International University of Health and Welfare (IUHW), in accordance with The Rules 
of Animal Experiments of the IUHW.   
 
Pharmacokinetic study of clenbuterol in rats  
     Rats were randomly divided into six groups.  The rats in the first and second 
groups were given (rac)-clenbuterol at a dose of 2 mg/kg via the intravenous (i.v.) or 
intraduodenal (i.d.) route, respectively.  A third group of rats received (-)-R-clenbuterol 
i.v. at a dose of 1 mg/kg.  The femoral artery and vein were cannulated under 
anesthesia with diethylether, and the abdominal cavity of the second group of rats was 
opened for cannulation into the duodenum.  Animals were given (rac) or 
(-)-R-clenbuterol dissolved in phosphate-buffered saline (pH 7.4) after they had 
recovered from anesthesia.  An appropriate volume of the dosing solution (ca. 2 mL/kg) 
was given to each of the animals through the femoral vein cannula, and the cannula was 
flushed with 0.5 mL of normal saline.  Blood samples (250 µL) were collected through 
the arterial cannula at 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 60 and 72 hours after administration 
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of the drug, and the lost fluid was replaced with an equal volume of saline via the vein 
cannula.  The blood samples were placed in heparinized tubes.  Plasma was obtained 
by centrifugation at 18,000 rpm for 5 min and stored at -30°C until analysis.  The 
concentrations of clenbuterol enantiomers were determined by LC-MS/MS. 
 
In-situ permeability studies  
     The permeability of rat intestinal membrane was evaluated by the in situ intestinal 
closed-loop method.  In a fourth group of rats, the abdominal cavity was opened, and an 
intestinal loop (length: 10 cm) was made at the upper jejunum by cannulation with 
polypropylene tubing. Both ends of the loop were ligated under anesthesia with 
diethylether.  The test solution containing (rac)-clenbuterol 100 µg/0.5 mL was 
introduced into the intestinal loop.  At various times, the luminal solution in the loop and 
the washing obtained with 7 mL saline were collected. The supernatant fluid was 
analyzed.  The intestinal loops were homogenized, extracted and analyzed.  The 
permeability of clenbuterol enantiomers was evaluated in terms of the percentage of 
dose absorbed, calculated by subtracting the remaining amount of clenbuterol in 
intestinal loops from the administered amount. 
 
Urinary Excretion  
     The femoral artery, vein and urinary bladder of a fifth group of rats were cannulated 
under anesthesia with diethylether.  (rac)-Clenbuterol 2 mg/kg was administered as an 
i.v. bolus dose through the femoral vein.  Urine was collected at 3, 6, 12, and 24 hours 
after dosing.  The volume of the collected urine was measured, and the urine was stored 
at -30°C until analysis.  Blood samples (250 µL) were collected through the arterial 
cannula at 0.5, 1, 3, 6, 9, 12 and 24 hours after dosing, and the lost fluid was replaced 
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with an equal volume of saline.  The blood samples were collected into heparinized 
tubes. Plasma samples were obtained by centrifugation at 18,000 rpm for 5 min and 
stored at -30°C until analysis. 
 
Biliary Excretion  
     The femoral artery and vein were cannulated in a sixth group of rats, and the 
abdominal cavity was opened for cannulation of the common bile duct under anesthesia 
with diethylether.  (rac)-Clenbuterol 2 mg/kg was administered as an i.v. bolus dose 
through the femoral vein.  Bile was collected at 3, 6, 12, and 24 hours after dosing.  
The volume of collected bile was measured, and the bile was stored at -30°C until 
analysis.  Blood samples (250 µL) were collected through the arterial cannula at 0.5, 1, 
3, 6, 9, 12 and 24 hours after dosing of the drug, and the lost fluid was replaced with an 
equal volume of saline.  The blood samples were collected into heparinized tubes. 
Plasma samples were obtained by centrifugation at 18,000 g for 5 min and stored at 
-30°C until analysis. 
 
Protein binding study  
     Plasma protein binding of (-)-R- and (+)-S-clenbuterol was determined using the 
ultrafiltration technique.  Appropriate amounts of (rac)-clenbuterol were added to rat 
drug-free plasma to give final concentrations of 20, 100 and 200 ng/mL (10, 50 and 100 
ng/mL, respectively, as enantiomer concentration).  The plasma samples were 
incubated at 37°C for 30 min.  One milliliter of each sample was then loaded onto a 
Centrifree® UF Device (Millipore Co, Billerica, MA).  The tube assembly was centrifuged 
at 2,000 g for 10 min at room temperature.  The protein-free ultrafiltrate was collected for 
drug analysis.  Before centrifugation, another 0.1 mL of the plasma sample was saved 
for analysis of the total drug concentration.  Protein unbound fraction was calculated 
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according to the following equation: 
% protein unbound fraction =  unbound clenbuterol concentration total clenbuterol concentration × 100 
 
Data Analysis  
     Plasma concentration-time profiles were subjected to non-compartmental 
pharmacokinetics analysis using the macro-program MOMENT (EXCEL) [25].  The area 
under the plasma concentration-time curve from time zero to time T, AUC0-T, where T is 
the time of last measurable concentration, was calculated using the linear trapezoidal 
method.  The area under the plasma concentration-time curve from time zero to infinity 
(AUC0-∞) and the area under the first-moment time curve (AUMC) were determined by 
using the combined log-linear trapezoidal rule and the extrapolated area.  Mean 
residence time (MRT) was calculated using the equation MRT = AUMC/ AUC0-∞.  The 
apparent elimination half-life (t1/2) was calculated as 0.693/ke and the ke was estimated 
by linear regression of the plasma concentration in the log-linear terminal phase.  
Clearance (CLtot) following i.v. dosing was calculated as Dose/AUC0-∞.  The apparent 
volume of distribution (Vdss) was estimated as MRT x CLtot. 
     The absolute bioavailabilty (%F) of clenbuterol enantiomers was calculated using 
the relationship.  
%F = [AUC0-∞( i.d.) x Dose(i.v.)/ AUC0-∞(i.v.) x Dose(i.d.)] x 100 
     The urinary clearance (CLr) and biliary clearance (CLbile) were obtained by dividing 
the amount excreted into the urine and bile by the area under the concentration-time 
curve from time zero to time 24 hours (AUC0→24). 
 
Chiral Inversion and Degradation in Buffer and Plasma Solutions  
     Enantiomeric stability was evaluated by measuring changes in the concentrations 
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of (-)-R- and (+)-S-clenbuterol in 0.1 M phosphate buffer pH 7.4 and rat plasma.  The 
sample solutions consisted of (-)-R- and (+)-S-clenbuterol 10 ng/mL in 0.1 M phosphate 
buffer pH 7.4 and rat plasma. Aliquots of 100 µL of these solutions were incubated at 
37°C for 0, 24, and 72 hours, and then stored at -30°C until analysis. 
 
Statistical Analysis 
     Values are expressed as means ± S.D.  Statistical analysis was performed by 





Pharmacokinetics of clenbuterol enantiomers in rats 
     To clarify the pharmacokinetic disposition of clenbuterol enantiomers in the rat, we 
examined plasma concentrations of each enantiomer after intravenous administration of 
(rac)-clenbuterol.  Plasma concentration-time profiles of clenbuterol enantiomers in rats 
after i.v. administration of 2 mg/kg (rac)-clenbuterol are shown in Figure 1.  Initially, 
(+)-S-clenbuterol showed a higher plasma concentration, but at 24 hours, the plasma 
concentration of (-)-R-clenbuterol was higher than that of (+)-S-clenbuterol.   
     The pharmacokinetic parameters of (-)-R- and (+)-S-clenbuterol estimated following 
i.v. administration of 2 mg/kg (rac)-clenbuterol are summarized in Table 2.  The AUC0-∞ 
values of (-)-R-clenbuterol and (+)-S-clenbuterol were 1.25 ± 0.18 μg/mL∙hr and 1.51 ± 
0.35 μg/mL∙hr, respectively (mean ± S.D., n = 4).  The CLtot of (-)-R-clenbuterol (13.5 ± 
1.8 mL/min/kg) was significantly higher than that of the S-enantiomer (11.5 ± 2.7 
mL/min/kg, p < 0.05).  The MRT of (-)-R-clenbuterol was significantly longer than that of 
(+)-S-clenbuterol.  The Vdss of (-)-R-clenbuterol (9.17 ± 2.76 L/kg) was larger than that 
of the S-enantiomer (4.14 ± 1.00 L/kg, p < 0.05).   
     Next, intraduodenal administration experiments were performed in rats.  Plasma 
concentration-time profiles of clenbuterol enantiomers in rat after i.d. administration of 2 
mg/kg (rac)-clenbuterol are shown in Figure 2.  Both enantiomers were absorbed rapidly, 
and the maximal concentrations (Cmax) for (-)-R- and (+)-S-clenbuterol, reached within 15 
min after administration, were 124.8 and 195.1 ng/mL, respectively.  As observed in i.v. 
administration, (+)-S-clenbuterol showed a higher blood concentration at the early times 
after dosage, but after 24 hours, the plasma concentration of (-)-R-clenbuterol was higher 
than that of (+)-S-clenbuterol. 
     The pharmacokinetic parameters for (-)-R- and (+)-S-clenbuterol, estimated 
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following i.d. administration of 2 mg/kg (rac)-clenbuterol, are also summarized in Table 2.  
(-)-R- and (+)-S-clenbuterol were almost completely absorbed and the bioavailabilities (F) 
after intraduodenal administration were 92% and 101%, respectively.  The mean CLtot/F 
of (-)-R-clenbuterol was 15.6 ± 3.8 mL/min/kg, which is higher than that of the 
S-enantiomer (11.7 ± 3.5 mL/min/kg, p < 0.05).  The mean Vdss/F of (-)-R-clenbuterol 
was 10.3 ± 2.9 L/kg, which is also higher than that of the S-enantiomer (5.0 ± 1.5 L/kg, p 
< 0.05). 
 
In-situ permeability study  
     To clarify whether it is different in intestinal absorption between the enantiomers, 
the absorption rate of the enantiomers was determined in rat jejunum by in situ closed 
loop method.  The fractions of (-)-R- and (+)-S-clenbuterol absorbed in the jejunal loop 
at 10 min after administration were 31.7% and 32.0%, respectively.  The fractions 
absorbed at 30 min after administration were 72.9％ and 73.3％, and those at 1 hour 
were 87.8% and 87.4%, respectively. There was no significant difference between the 
enantiomers at any time point examined.   
 
Urinary elimination  
     The urinary excretion of the clenbuterol enantiomers was determined after i.v. 
dosing to rats.  Excretions of (-)-R- and (+)-S-enantiomers in urine over 24 hours were 
19.7 ± 1.2%, and 22.3 ± 1.5% of the administered dose, respectively (Figure 3).  
Calculated renal clearance (CLr) values of the (-)-R- and (+)-S-enantiomers were 4.9 ± 
0.7 mL/min/kg, and 4.5 ± 0.9 mL/min/kg, respectively, showing no significant difference. 
 
Biliary excretion  
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     Next, the clenbuterol concentrations in bile were determined after i.v. dosing to rats.  
About 9.3 to 14.4 mL of bile was obtained from each rat during 24 hours after i.v. dosing 
of clenbuterol.  It was found that amounts of about 7.7 ± 1.8%, and 3.3 ± 0.4% of the 
administered dose were recovered cumulatively in the bile collected up to 24 hours 
(Figure 4) for (-)-R-clenbuterol and (+)-S-clenbuterol, respectively.  Calculated biliary 
clearance (CLbile) of (-)-R-clenbuterol (1.62 ± 0.88 mL/min/kg) was markedly higher than 
that of the (+)-S-enantiomer (0.45 ± 0.23 mL/min/kg). 
 
Protein binding  
     The protein-unbound ratio has a substantial influence on drug distribution, so we 
examined in vitro protein binding of clenbuterol.  The unbound fraction of clenbuterol, 
estimated by ultrafiltration of rat plasma spiked with (rac)-clenbuterol, showed no marked 
concentration dependence between 20 and 200 ng/mL clenbuterol. However, there was 
a marked difference between the two enantiomers. Unbound fractions of 
(-)-R-clenbuterol were 52.6, 46.4, and 47.6% at the concentrations of 10, 50, and 100 
ng/mL (-)-R-clenbuterol, respectively. Unbound fractions of (+)-S-clenbuterol were 34.0, 
31.4, and 33.9% at the concentrations of 10, 50, and 100 ng/mL (+)-S-clenbuterol, 
respectively.  The mean unbound fractions of (-)-R-clenbuterol and (+)-S-clenbuterol 
were 48.8 ± 3.1 and 33.1 ± 1.5%, respectively. 
 
Tissue distribution 
    Table 3 shows the tissue-to-plasma concentration ratios (Kp) and the 
tissue-to-plasma free concentration ratios (Kp,f) of (-)-R-clenbuterol and (+)-S-clenbuterol 
in various tissues at 36 hours after i.v. administration of (rac)-clenbuterol.  The Kp,f as 
well as Kp values of (+)-S-clenbuterol in the liver, kidney, lung and muscle were 
significantly greater than those of the (-)-R-enantiomer. 
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 Chiral inversion in vitro and in vivo  
    Experiments were carried out to evaluate whether clenbuterol enantiomers undergo 
chiral inversion and degradation in buffer or plasma, or in vivo.   
     The peak area of (-)-R-clenbuterol enantiomer in PBS (pH 7.4) and rat plasma 
showed no significant change during 72 hours incubation, and no peak of the 
(+)-S-enantiomer was detected (data not shown).  A similar result was obtained for the 
(+)-S-enantiomer.  The (+)-S-clenbuterol used consisted of 93.0% (+)-S-clenbuterol and 
7.0% (-)-R-clenbuterol, and the (+)-S-clenbuterol/(-)-R-clenbuterol ratio remained 
unchanged during 72 hours incubation.  Thus, inversion or degradation did not occur up 
to 72 hours.   
     Plasma concentration-time profiles of clenbuterol enantiomers in rat after 
intravenous administration of 1 mg/kg (-)-R-clenbuterol are shown in Figure 5.  No 




     In this study, we found that Vdss, CLtot and MRT were significantly different (2.2-fold, 
1.2-fold and 1.9-fold, respectively) for the two enantiomers of clenbuterol in rats (Table 2).  
There was also a difference in protein binding between the enantiomers (1.5-fold). 
The enantioselective protein binding of clenbuterol might account for the 
enantioselectivity of systemic clearance, but it was not sufficient to explain the difference 
in Vdss of the enantiomers. Given the biliary clearance of clenbuterol and the rapid and 
complete absorption after intraduodenal administration (Table 2), the existence of 
entero-hepatic circulation seems likely.  Indeed, Manchee et al. [26] reported that the 
β2-adrenoceptor agonist salmeterol undergoes entero-hepatic circulation.  Therefore, 
we think a difference in entero-hepatic circulation of clenbuterol enantiomers could 
contribute to the enantioselectivity of Vdss as well as MRT.  Moreover, enantioselective 
tissue-binding should also be considered.  Accordingly, enantioselectively in tissue 
uptake or membrane transport processes, i.e., from sinusoidal uptake to biliary excretion, 
and/or transport in the renal tubules might contribute to the enantioselective systemic 
clearance. 
In our preliminary study, the tissue concentrations of (-)-R- and (+)-S-clenbuterol 
were evaluated at 3 hours and 24 hours after administration. The Kp values of (-)-R- and 
(+)-S-clenbuterol in the lung were 52.3 / 43.6 and 11.7 / 19.9 at 3 hours and 24 hours, 
respectively.  Those in the liver were 63.7 / 49.2 and 10.7 / 19.2 at 3 hours and 24 hours, 
respectively.  The Kp values of (-)-R-clenbuterol were larger than those of 
(+)-S-clenbuterol at early time points after administration.  These results may reflect the 
larger distribution volume of (-)-R-clenbuterol compared to (+)-S-clenbuterol.  However, 
we cannot exclude the possibility that the distribution process to tissues was incomplete.  
Therefore, we determined Kp,f values at 36 hours after administration, by which time 
equilibration between blood and tissues should be completed.  The Kp,f values of 
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(+)-S-clenbuterol in liver and kidney were significantly greater than those of the 
(-)-R-enantiomer at 36 hours after administration (Table 3).  This result is consistent with 
the findings of von Deutsch et al. [14] and Smith [27], who reported that the 
concentrations of (+)-S-clenbuterol in these organs were greater than those of the 
(-)-R-enantiomer after repeated dosing of clenbuterol, although they did not determine 
blood concentrations.  The difference of Kp values estimated at 36 hours may reflect 
irreversible tissue binding of the (+)-S-enantiomer, which could be related to the side 
effects of the (+)-S-enantiomer. 
 We also found that the CLtot of (-)-R-clenbuterol (13.5 mL/min/kg) was slightly but 
significantly higher than that of the (+)-S-enantiomer (11.5 mL/min/kg).  However, no 
significant difference between the enantiomers was observed in urinary clearance and 
metabolic clearance (estimated as non-renal and non-biliary clearance).  The only 
significant difference between (-)-R-clenbuterol and (+)-S-clenbuterol was observed in 
biliary clearance (1.62 ± 0.88 mL/min/kg and 0.45 ± 0.23 mL/min/kg, respectively).  The 
difference of plasma protein binding may also affect the uptake of clenbuterol by the liver, 
thereby influencing CLbile of (-)-R- and (+)-S-clenbuterol.  Although the contributions of 
(-)-R- and (+)-S-clenbuterol biliary clearance to CLtot are small, i.e., 12% and 4%, 
respectively, the difference in biliary clearance may contribute to the enantioselectivity of 
CLtot.   
     The glomerular filtration rate of rats is reported to be 5.24 mL/min/kg [28].  
Estimated values of fp×glomerular filtration rate of (-)-R and (+)-S-clenbuterol based on 
the plasma protein binding rates were 2.6 and 1.7 mL/min/kg, respectively.  The values 
of clearance ratio (=CLr,u/(GFR*fp)) for (-)-R- and (+)-S-clenbuterol (1.9, and 2.6, 
respectively) suggest that reabsorption occurred during the urinary excretion process.  
     Plasma protein binding of (rac)-clenbuterol was reported to be 68-70%.  In this 
study, the average of (-)-R- and (+)-S-clenbuterol plasma protein-binding rates was 59%, 
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which is similar to the reported range.  The unbound fraction of (-)-R- and 
(+)-S-clenbuterol were 0.488 and 0.331, respectively, and this may have contributed 
substantially to the differences of Vdss and excretion between the enantiomers observed 
in this study.  Very recently, enantioselectivity in serum protein binding of a β1-blocker 
with β3 agonistic property, nevivolol, has been reported by Sanaee et al [29]. The 
unbound fraction of (-)-nebivolol (0.112) was significantly higher than that of (+)-nebibolol 
(0.061), which resulted in the systemic stereoselectivity.  However, it has also been 
reported that the tissue binding of salbutamol is not enantioselective and plasma protein 
binding is relatively low [11].  Therefore, differences appear to exist even between 
medicines in the same category, so it is important to evaluate each medicine individually.    
     The MRT0-∞ of (-)-R-clenbuterol was about twice that of (+)-S-clenbuterol.  Since 
(-)-R-clenbuterol exerts the desired therapeutic effect, this is favorable.  On the other 
hand, Cmax of (+)-S-clenbuterol was larger than that of the (-)-R-enantioner.  Since 
(+)-S-clenbuterol has side effects including increased blood pressure and increased 
blood sugar level and glucocorticoid, it is undesirable for Cmax to be high.  Moreover, it 
was predicted from CLtot that the steady-state plasma concentration of (+)-S-clenbuterol 
would be higher than that of (-)-R-clenbuterol.  Beta2-stimulant activities such as 
bronchodilation and uterine relaxing activity are almost exclusively exhibited by 
(-)-R-clenbuterol.  On the other hand, (+)-S-clenbuterol has been reported to cause 
adverse effects such as reduction of blood pressure, increase of blood glucose level, and 
elevation of glucocorticoid level.  Clenbuterol treatment improves muscular functional 
capacity by increasing muscular strength.  However, our unpublished data indicate that 
(-)-R-clenbuterol is responsible for muscle reinforcement, while (+)-S-clenbuterol acts to 
reduce bone density.  Because (+)-S-clenbuterol clearance is smaller, and 
(+)-S-clenbuterol tissue distribution is larger than those of (-)-R-clenbuterol, the adverse 
effects of (+)-S-clenbuterol cannot be ignored.  Therefore, we believe it would be 
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preferable for pharmaceutical products to contain only (-)-R-clenbuterol.  We think the 
racemate should not be used as an aid for muscle-building. 
Thus, we believe development of enantiomerically pure (-)-R-clenbuterol as a 
therapeutic agent would be desirable. Fortunately, we found that no enantiomeric 
conversion of clenbuterol occurred in the in vitro and in vivo experiments. This is in 
contrast to thalidomide, whose optical isomers are interconverted in PBS [5,6] and 
MK-0767 [30], a dual peroxisome proliferator-activated receptor agonist, whose 
enantiomers are interconverted in plasma even though they are stable in PBS. These 
results suggest that it may be feasible to develop enantiomerically pure (-)-R-clenbuterol 




     We examined the disposition of (-)-R- and (+)-S-clenbuterol following i.v. and i.d. 
administration of (rac)-clenbuterol in rats.  Our results suggest that the distribution and 
excretion characteristics of (-)-R-clenbuterol and (+)-S-clenbuterol are significantly 
different, and these differences seem to be predominantly due to a difference in protein 
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Plasma concentration versus time curves for (-)-R-clenbuterol (closed circles) and 
(+)-S-clenbuterol (open circles) after i.v. administration of 2 mg/kg (rac)-clenbuterol to 
rats. (n = 4, Mean ± S.D.) *p < 0.05, (-)-R-clenbuterol vs. (+)-S-clenbuterol. 
 
Figure 2. 
Plasma concentration versus time curves (-)-R-clenbuterol (closed circles) and 
(+)-S-clenbuterol (open circles) after i.d. administration of 2 mg/kg (rac)-clenbuterol to 
rats. (n = 5, Mean ± S.D.) *p < 0.05, (-)-R-clenbuterol vs. (+)-S-clenbuterol. 
 
Figure 3. 
Cumulative urinary excretion ratio (-)-R-clenbuterol (closed circles) and (+)-S-clenbuterol 
(open circles) after i.v. administration of 2 mg/kg (rac)-clenbuterol to rats. (n = 5, Mean ± 
S.D.). *p < 0.05, (-)-R-clenbuterol vs. (+)-S-clenbuterol. 
 
Figure 4. 
Cumulative biliary excretion ratio of (-)-R-clenbuterol (closed circles) and 
(+)-S-clenbuterol (open circles) after i.v. administration of 2 mg/kg (rac)-clenbuterol to 
rats. (n = 5, Mean ± S.D.). *p < 0.05, (-)-R-clenbuterol vs. (+)-S-clenbuterol.  
 
Figure 5. 
Plasma concentration versus time curves for (-)-R-clenbuterol (closed circles) after i.v. 




Intra- and inter-day precision and accuracy in determination of clenbuterol enantiomers in rat 
plasma. 
 
 Nominal Mean ± S.D. Accuracya C.V.b 
 (ng/mL) (ng/mL)  (%) (%) 
 
Intra-day (n = 6) 
 (-)-R-clenbuterol 1 0.97 0.05 97.0 2.7 
  5 5.03 0.19 100.6 4.3 
  25 25.1 0.19 100.4 1.0 
 (+)-S-clenbuterol 1 0.97 0.04 97.0 3.2 
  5 5.01 0.24 100.2 4.5 
  25 24.9 0.14 99.6 1.4 
Inter-day (n = 6) 
 (-)-R-clenbuterol 1 1.04 0.04 104.0 3.6 
  5 4.63 0.1 92.6 2.1 
  25 25.4 0.36 101.6 1.4 
 (+)-S-clenbuterol 1 0.99 0.03 99.0 3.2 
  5 4.85 0.15 97.0 3.1 
  25 25.2 0.34 100.8 1.3 
 
a  Accuracy (%) is expressed as mean found concentration/nominal concentration × 100.  





Pharmacokinetic parameters of clenbuterol enantiomers after i.v. and i.d. administration of 2 
mg/kg (rac)-clenbuterol to rats. 
 
 (-)-R-clenbuterol (+)-S-clenbuterol 
 
i.v. 
AUC0→∞ (μg/mL･hr) 1.25 ± 0.18 1.51 ± 0.35  
MRT (hr) 11.2 ± 2.0 6.0 ± 0.7 * 
t1/2  (hr) 19.1 ± 5.5 14.1 ± 5.1 * 
CLtot  (mL/min/kg) 13.5 ± 1.8 11.5 ± 2.7 * 
Vdss  (L/kg) 9.17 ± 2.76 4.14 ± 1.00 * 
 
i.d. 
AUC0→∞ (μg/mL･hr) 1.15 ± 0.42 1.52 ± 0.46 *  
MRT (hr) 11.1 ± 2.1 7.1 ± 0.7 * 
t1/2  (hr) 12.9 ± 4.9 5.4 ± 1.0 * 
F (%) 92.0 ± 33.6 101.0 ± 30.2 
CLtot/F  (mL/min/kg) 15.6 ± 3.8 11.7 ± 3.5 * 
Vdss/F  (L/kg) 10.3 ± 2.9 5.0 ± 1.5 * 
 
Upper: Moment analysis of clenbuterol from plasma concentration after i.v. administration of 
(rac)-clenbuterol (2 mg/kg) to rats (298 ± 27 g, n = 4).  
Lower: Moment analysis of clenbuterol from plasma concentration after i.d. administration of 
(rac)-clenbuterol (2 mg/kg) to rats (235 ± 29 g, n = 5).  
* Significant difference between (-)-R-clenbuterol and (+)-S-clenbuterol at p < 0.05; Student’s t test. 
 AUC0→∞, area under the plasma concentration-time curve from time zero to infinity; MRT, mean 
residence time; t1/2, terminal half-life; CLtot, total body clearance; Vdss, distribution volume at steady 
state.   
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Table 3 
Tissue-to-plasma concentration ratio (Kp) of (-)-R-clenbuterol and (+)-S-clenbuterol at 36 hours 
after intravenous administration of (rac)-clenbuterol. 
 
Tissue (-)-R-clenbuterol (+)-S-clenbuterol 
 Kp (Kp,f) Kp (Kp,f) 
 
Lung 2.63 ± 1.04 (5.01 ± 1.97) 9.75 ± 4.69 * (28.7 ± 13.8 *) 
Liver  5.28 ± 2.19 (10.0 ± 4.2) 24.9 ± 5.8 * (73.1 ± 17.1 *) 
Kidney  1.99 ± 0.65 (3.79 ± 1.24)  11.8 ± 3.0 * (34.8 ± 8.9 *) 
Muscle  0.58 ± 0.28 (1.10 ± 0.54) 1.91 ± 0.60 * (5.61 ± 1.75 *) 
 
(rac)-Clenbuterol (2 mg/kg) was administered intravenously to rats.  At 36 hours after administration, 
rats were decapitated and the plasma and tissues were isolated and weighed.  The tissue and 
plasma contents and plasma unbound fractions of (-)-R-clenbuterol and (+)-S-clenbuterol were 
determined as described in Materials and Methods.  Each value represents the mean ± S.D. (n = 5).  
* Significantly different between (-)-R-clenbuterol and (+)-S-clenbuterol at p < 0.05; Student’s t test. 
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